GLP‑1s Boost Meat Demand

Both the existing idea and this article concern the systemic effects of a new class of metabolic drugs: GLP‑1 medications altered diet and demand patterns, and pTOS is a candidate appetite‑suppressing drug with a different biology; if pTOS or similar agents scale to humans they could generate parallel economic, dietary, and regulatory ripple effects (pharma markets, coverage, food demand). The article names Stanford, the Nature Metabolism paper, and mouse weight‑loss results as the concrete link.

The article juxtaposes diet‑first approaches with drugs like Ozempic, implying dietary guidance and pharmacologic trends interact; that links to the existing observation that GLP‑1 adoption has shifted food demand (meat sales). The piece’s claim that diet programs can rival drugs is the empirical hinge connecting to the existing fact‑narrative.

“Americans are eating more meat… eating more meat to replace the muscle mass lost with weight‑loss drugs,” alongside a record $105 billion in 2024 meat sales and plant‑based at only 1%.